Evaluating the Therapeutic Impact of Targeted Therapy in Advanced Breast Cancers including TNBC
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Triple-negative breast cancer (TNBC) represents one of the most aggressive and clinically challenging subtypes of breast cancer, characterized by a poor prognosis and high rates of recurrence.Although chemotherapy is the main treatment option with TNBC, the effectiveness of chemotherapy for TNBC is still limited.In addition, TNBC has its unique composition of lacking three common receptors in breast cancer such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2), which makes TNBC hard to treat due to lack of specific therapeutic targets.Despite its molecular heterogeneity, advances in wholegenome sequencing studies have enabled the identification of distinct molecular subtypes within TNBC, offering new insights into the tumor's underlying biology.Recent studies also have identified specific genetic alterations and aberrant signaling pathways to explore novel targeted therapeutic strategies.These efforts have led to development of several targeted therapeutic agents including, Poly (ADPribose) polymerase inhibitors (PARPi), Androgen Receptor (AR) antagonists, Cyclin-Dependent Kinase (CDK) 4/6 inhibitors, Phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway inhibitors, Epidermal Growth Factor Receptor (EGFR) signaling pathway inhibitors, and immune checkpoint inhibitors targeting Programmed Death Receptor (PD-1) or Program-cell Death-Ligand 1 (PD-L1).In this study, we summarize multiple targeted therapies in patients with advanced breast cancer, mostly focusing on TNBC, with an emphasis on the mechanism of action of each drug class and their clinical efficacy such as overall survival, progression-free survival, or objective response rates.
Fields of Study & Subjects
Breast Cancer Treatment Studies
Advanced Breast Cancer Therapies
PARP inhibition in cancer therapy
Publication details
- Publication date
- 27 March 2026
- Language
- EN